{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T20:37:29Z","timestamp":1793824649669,"version":"4.6.1"},"reference-count":118,"publisher":"MDPI AG","issue":"23","license":[{"start":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T00:00:00Z","timestamp":1764028800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Gastrointestinal cancers, including gastric, gastroesophageal junction, pancreatic, and biliary tract cancers, remain associated with poor outcomes due to late diagnosis and limited effective treatment options. Claudin-18.2 (CLDN18.2), a tight junction protein primarily found in the gastric epithelium and ectopically expressed in gastrointestinal tumors, has emerged as a promising therapeutic target across these diseases. This narrative review expands on existing discussions surrounding CLDN18.2-directed therapy in gastric and gastroesophageal cancer and provides a comprehensive, updated analysis of the rapidly evolving therapeutic landscape across multiple gastrointestinal malignancies, including pancreatic and biliary tract cancers. We summarize key developments following the approval of the monoclonal antibody zolbetuximab and critically evaluate emerging modalities, including bispecific antibodies, antibody\u2013drug conjugates, and chimeric antigen receptor T-cell therapies, highlighting differences in mechanisms of action, efficacy, toxicity profiles, and mitigation strategies. We also discuss the clinical relevance of CLDN18.2 and PD-L1 co-expression, the rationale for pairing CLDN18.2-targeted therapy with immune checkpoint inhibitors, and early data supporting combination approaches. Additionally, we examine tumor heterogeneity, biomarker challenges, and emerging resistance mechanisms, alongside strategies to overcome them. Finally, we identify current limitations in the field, including inconsistent CLDN18.2 testing criteria, and outline prioritized future directions to optimize integration of CLDN18.2-directed therapies across gastrointestinal cancers. By looking beyond zolbetuximab and incorporating cross-platform comparison, immuno-oncology considerations, and multi-tumor context, this review provides a broad and forward-looking framework to guide clinical application and next-generation research in CLDN18.2-targeted therapy.<\/jats:p>","DOI":"10.3390\/cancers17233764","type":"journal-article","created":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T15:29:47Z","timestamp":1764084587000},"page":"3764","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["CLDN18.2-Targeted Therapy in Gastrointestinal Cancers"],"prefix":"10.3390","volume":"17","author":[{"given":"Andrea","family":"Dominguez Wiscovitch","sequence":"first","affiliation":[{"name":"Department of Medicine, NYU Langone Health, New York, NY 10016, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-3902-9314","authenticated-orcid":false,"given":"Ricardo J.","family":"Sanchez Mendez","sequence":"additional","affiliation":[{"name":"NYU Grossman School of Medicine, NYU Langone Health, New York, NY 10016, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Chuy","sequence":"additional","affiliation":[{"name":"Perlmutter Cancer Center, NYU Langone Health, New York, NY 10016, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,11,25]]},"reference":[{"key":"ref_1","first-page":"229","article-title":"Global Cancer Statistics 2022: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA A Cancer J Clin."},{"key":"ref_2","first-page":"10","article-title":"Cancer Statistics, 2025","volume":"75","author":"Siegel","year":"2025","journal-title":"CA A Cancer J Clin."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/S0140-6736(21)00153-7","article-title":"Biliary Tract Cancer","volume":"397","author":"Valle","year":"2021","journal-title":"Lancet"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"7624","DOI":"10.1158\/1078-0432.CCR-08-1547","article-title":"Claudin-18 Splice Variant 2 Is a Pan-Cancer Target Suitable for Therapeutic Antibody Development","volume":"14","author":"Sahin","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1967080","DOI":"10.1080\/21688370.2021.1967080","article-title":"Claudin-18.2 as a Therapeutic Target in Cancers: Cumulative Findings from Basic Research and Clinical Trials","volume":"10","author":"Kyuno","year":"2022","journal-title":"Tissue Barriers"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/s00428-011-1092-z","article-title":"Claudin-18 in Biliary Neoplasms. Its Significance in the Classification of Intrahepatic Cholangiocarcinoma","volume":"459","author":"Shinozaki","year":"2011","journal-title":"Virchows Arch."},{"key":"ref_7","unstructured":"(2025, June 12). U.S. Food and Drug Administration FDA Grants Approval to Zolbetuximab with Chemotherapy for Gastric or GEJ Adenocarcinoma 2024, Available online: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-zolbetuximab-clzb-chemotherapy-gastric-or-gastroesophageal-junction-adenocarcinoma."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1016\/S0140-6736(23)00620-7","article-title":"Zolbetuximab plus mFOLFOX6 in Patients with CLDN18.2-Positive, HER2-Negative, Untreated, Locally Advanced Unresectable or Metastatic Gastric or Gastro-Oesophageal Junction Adenocarcinoma (SPOTLIGHT): A Multicentre, Randomised, Double-Blind, Phase 3 Trial","volume":"401","author":"Shitara","year":"2023","journal-title":"Lancet"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1038\/s41591-023-02465-7","article-title":"Zolbetuximab plus CAPOX in CLDN18.2-Positive Gastric or Gastroesophageal Junction Adenocarcinoma: The Randomized, Phase 3 GLOW Trial","volume":"29","author":"Shah","year":"2023","journal-title":"Nat. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1152\/physrev.00019.2012","article-title":"Claudins and the Modulation of Tight Junction Permeability","volume":"93","author":"Yu","year":"2013","journal-title":"Physiol. Rev."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1186\/s13045-017-0473-4","article-title":"Anti-Claudin 18.2 Antibody as New Targeted Therapy for Advanced Gastric Cancer","volume":"10","author":"Singh","year":"2017","journal-title":"J. Hematol. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Sato, K., Matsumoto, I., Suzuki, K., Tamura, A., Shiraishi, A., Kiyonari, H., Kasamatsu, J., Yamamoto, H., Miyasaka, T., and Tanno, D. (2021). Deficiency of Lung-Specific Claudin-18 Leads to Aggravated Infection with Cryptococcus Deneoformans through Dysregulation of the Microenvironment in Lungs. Sci. Rep., 11.","DOI":"10.1038\/s41598-021-00708-6"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1165\/rcmb.2013-0456OC","article-title":"Claudin-18 Deficiency Results in Alveolar Barrier Dysfunction and Impaired Alveologenesis in Mice","volume":"51","author":"LaFemina","year":"2014","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"G1106","DOI":"10.1152\/ajpgi.00158.2007","article-title":"Claudin-18: A Dominant Tight Junction Protein in Barrett\u2019s Esophagus and Likely Contributor to Its Acid Resistance","volume":"293","author":"Jovov","year":"2007","journal-title":"Am. J. Physiol.-Gastrointest. Liver Physiol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1053\/j.gastro.2011.10.040","article-title":"Deficiency of Claudin-18 Causes Paracellular H+ Leakage, Up-Regulation of Interleukin-1\u03b2, and Atrophic Gastritis in Mice","volume":"142","author":"Hayashi","year":"2012","journal-title":"Gastroenterology"},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Chen, J., Xu, Z., Hu, C., Zhang, S., Zi, M., Yuan, L., and Cheng, X. (2023). Targeting CLDN18.2 in Cancers of the Gastrointestinal Tract: New Drugs and New Indications. Front. Oncol., 13.","DOI":"10.3389\/fonc.2023.1132319"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"14271","DOI":"10.18632\/aging.103457","article-title":"Analysis of the Expression and Genetic Alteration of CLDN18 in Gastric Cancer","volume":"12","author":"Li","year":"2020","journal-title":"Aging"},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Wu, J., Lu, J., Chen, Q., Chen, H., Zheng, Y., and Cheng, M. (2024). Pan-Cancer Analysis of CLDN18.2 Shed New Insights on the Targeted Therapy of Upper Gastrointestinal Tract Cancers. Front. Pharmacol., 15.","DOI":"10.3389\/fphar.2024.1494131"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1093\/jjco\/hyz068","article-title":"Comparison of Claudin 18.2 Expression in Primary Tumors and Lymph Node Metastases in Japanese Patients with Gastric Adenocarcinoma","volume":"49","author":"Rohde","year":"2019","journal-title":"Jpn. J. Clin. Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1038\/s41416-019-0508-4","article-title":"Claudin-18 Expression in Oesophagogastric Adenocarcinomas: A Tissue Microarray Study of 523 Molecularly Profiled Cases","volume":"121","author":"Coati","year":"2019","journal-title":"Br. J. Cancer"},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Pellino, A., Brignola, S., Riello, E., Niero, M., Murgioni, S., Guido, M., Nappo, F., Businello, G., Sbaraglia, M., and Bergamo, F. (2021). Association of CLDN18 Protein Expression with Clinicopathological Features and Prognosis in Advanced Gastric and Gastroesophageal Junction Adenocarcinomas. J. Pers. Med., 11.","DOI":"10.3390\/jpm11111095"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"100762","DOI":"10.1016\/j.esmoop.2022.100762","article-title":"Comprehensive Clinical and Molecular Characterization of Claudin 18.2 Expression in Advanced Gastric or Gastroesophageal Junction Cancer","volume":"8","author":"Kubota","year":"2023","journal-title":"ESMO Open"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/j.annonc.2021.02.005","article-title":"FAST: A Randomised Phase II Study of Zolbetuximab (IMAB362) plus EOX versus EOX Alone for First-Line Treatment of Advanced CLDN18.2-Positive Gastric and Gastro-Oesophageal Adenocarcinoma","volume":"32","author":"Sahin","year":"2021","journal-title":"Ann. Oncol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.1053\/j.gastro.2018.08.041","article-title":"Loss of Tight Junction Protein Claudin 18 Promotes Progressive Neoplasia Development in Mouse Stomach","volume":"155","author":"Hagen","year":"2018","journal-title":"Gastroenterology"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s12964-023-01406-8","article-title":"Claudin-18.2 Mediated Interaction of Gastric Cancer Cells and Cancer-Associated Fibroblasts Drives Tumor Progression","volume":"22","author":"Liu","year":"2024","journal-title":"Cell Commun. Signal"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"154699","DOI":"10.1016\/j.prp.2023.154699","article-title":"Correlation of Claudin18.2 Expression with Clinicopathological Characteristics and Prognosis in Gastric Cancer","volume":"248","author":"Tao","year":"2023","journal-title":"Pathol.\u2014Res. Pract."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1038\/s41571-024-00874-2","article-title":"Claudin 18.2 as a Novel Therapeutic Target","volume":"21","author":"Nakayama","year":"2024","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Cao, W., Xing, H., Li, Y., Tian, W., Song, Y., Jiang, Z., and Yu, J. (2022). Claudin18.2 Is a Novel Molecular Biomarker for Tumor-Targeted Immunotherapy. Biomark. Res., 10.","DOI":"10.1186\/s40364-022-00385-1"},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Ungureanu, B.S., Lungulescu, C.-V., Pirici, D., Turcu-Stiolica, A., Gheonea, D.I., Sacerdotianu, V.M., Liliac, I.M., Moraru, E., Bende, F., and Saftoiu, A. (2021). Clinicopathologic Relevance of Claudin 18.2 Expression in Gastric Cancer: A Meta-Analysis. Front. Oncol., 11.","DOI":"10.3389\/fonc.2021.643872"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1111\/his.13797","article-title":"Mucin 5B, Carbonic Anhydrase 9 and Claudin 18 Are Potential Theranostic Markers of Gallbladder Carcinoma","volume":"74","author":"Espinoza","year":"2019","journal-title":"Histopathology"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1002\/ijc.28400","article-title":"Claudin 18.2 Is a Target for IMAB362 Antibody in Pancreatic Neoplasms","volume":"134","author":"Schlitter","year":"2014","journal-title":"Int. J. Cancer"},{"key":"ref_32","first-page":"971","article-title":"Immunohistochemical Analysis of Claudin Expression in Pancreatic Cystic Tumors","volume":"25","author":"Lee","year":"2011","journal-title":"Oncol. Rep."},{"key":"ref_33","first-page":"1031","article-title":"Investigation of Clinical Application of Claudin 18 Isoform 2 in Pancreatic Ductal Adenocarcinoma: A Retrospective Analysis of 302 Chinese Patients","volume":"37","author":"Zhang","year":"2022","journal-title":"Histol. Histopathol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"102044","DOI":"10.1016\/j.tranon.2024.102044","article-title":"Extent and Clinical Significance of the Therapy-Relevant Tight Junction Protein Claudin 18.2 in Pancreatic Ductal Adenocarcinoma\u2014Real-World Evidence","volume":"47","author":"Lyu","year":"2024","journal-title":"Transl. Oncol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"102362","DOI":"10.1016\/j.tranon.2025.102362","article-title":"Claudin 18 (43\u201314A Clone) Expression in Pancreatic Ductal Adenocarcinoma: Assessment of a Potential Clinical Biomarker for Zolbetuximab Therapy","volume":"55","author":"Arseneau","year":"2025","journal-title":"Transl. Oncol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"105049","DOI":"10.1016\/j.esmoop.2025.105049","article-title":"Claudin 18.2: A Promising Actionable Target in Biliary Tract Cancers","volume":"10","author":"Angerilli","year":"2025","journal-title":"ESMO Open"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1111\/his.15407","article-title":"Expression of Claudin-18.2 in Cholangiocarcinoma: A Comprehensive Immunohistochemical Analysis from a German Tertiary Centre","volume":"86","author":"Kinzler","year":"2025","journal-title":"Histopathology"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.canlet.2017.05.033","article-title":"Claudin-18 Coupled with EGFR\/ERK Signaling Contributes to the Malignant Potentials of Bile Duct Cancer","volume":"403","author":"Takasawa","year":"2017","journal-title":"Cancer Lett."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"217362","DOI":"10.1016\/j.canlet.2024.217362","article-title":"Emerging Targets in Gastric and Pancreatic Cancer: Focus on Claudin 18.2","volume":"611","author":"Tojjari","year":"2025","journal-title":"Cancer Lett."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1002\/path.1922","article-title":"Down-Regulation of the Claudin-18 Gene, Identified through Serial Analysis of Gene Expression Data Analysis, in Gastric Cancer with an Intestinal Phenotype","volume":"208","author":"Sanada","year":"2006","journal-title":"J. Pathol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1021\/acs.analchem.0c04055","article-title":"Ultrasensitive Gastric Cancer Circulating Tumor Cellular CLDN18.2 RNA Detection Based on a Molecular Beacon","volume":"93","author":"Fan","year":"2021","journal-title":"Anal. Chem."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"155145","DOI":"10.1016\/j.prp.2024.155145","article-title":"Claudin-18.2 Testing and Its Impact in the Therapeutic Management of Patients with Gastric and Gastroesophageal Adenocarcinomas: A Literature Review with Expert Opinion","volume":"254","author":"Angerilli","year":"2024","journal-title":"Pathol.\u2014Res. Pract."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"104000","DOI":"10.1016\/j.esmoop.2024.104000","article-title":"Clinicopathological Analysis of Claudin 18.2 Focusing on Intratumoral Heterogeneity and Survival in Patients with Metastatic or Unresectable Gastric Cancer","volume":"9","author":"Kim","year":"2024","journal-title":"ESMO Open"},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Wang, C., Wu, N., Pei, B., Ma, X., and Yang, W. (2023). Claudin and Pancreatic Cancer. Front. Oncol., 13.","DOI":"10.3389\/fonc.2023.1136227"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.4251\/wjgo.v14.i7.1252","article-title":"Claudin 18.2 Is a Potential Therapeutic Target for Zolbetuximab in Pancreatic Ductal Adenocarcinoma","volume":"14","author":"Wang","year":"2022","journal-title":"World J. Gastrointest. Oncol."},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Choi, E., Shin, J., Ryu, M.-H., Kim, H.-D., and Park, Y.S. (2024). Heterogeneity of Claudin 18.2 Expression in Metastatic Gastric Cancer. Sci. Rep., 14.","DOI":"10.1038\/s41598-024-68411-w"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"303","DOI":"10.5230\/jgc.2025.25.e2","article-title":"Discordance in Claudin 18.2 Expression Between Primary and Metastatic Lesions in Patients with Gastric Cancer","volume":"25","author":"Son","year":"2025","journal-title":"J. Gastric Cancer"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1007\/s10120-022-01298-6","article-title":"Association between HER2 Heterogeneity and Clinical Outcomes of HER2-Positive Gastric Cancer Patients Treated with Trastuzumab","volume":"25","author":"Bang","year":"2022","journal-title":"Gastric Cancer"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.trecan.2023.11.001","article-title":"Targeting HER2 Heterogeneity in Breast and Gastrointestinal Cancers","volume":"10","author":"Valenza","year":"2024","journal-title":"Trends Cancer"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1093\/annonc\/mdz199","article-title":"A Multicentre, Phase IIa Study of Zolbetuximab as a Single Agent in Patients with Recurrent or Refractory Advanced Adenocarcinoma of the Stomach or Lower Oesophagus: The MONO Study","volume":"30","author":"Sahin","year":"2019","journal-title":"Ann. Oncol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"3882","DOI":"10.1158\/1078-0432.CCR-23-0204","article-title":"ILUSTRO: Phase II Multicohort Trial of Zolbetuximab in Patients with Advanced or Metastatic Claudin 18.2-Positive Gastric or Gastroesophageal Junction Adenocarcinoma","volume":"29","author":"Klempner","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"4046","DOI":"10.1200\/JCO.2023.41.16_suppl.4046","article-title":"Osemitamab in Combination with Capecitabine and Oxaliplatin (CAPOX) as a First Line Treatment of Advanced G\/GEJ Cancer: Updated Data of Cohort C from a Phase I\/IIa, Multi-Center Study (TranStar102\/TST001-1002)","volume":"41","author":"Shen","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"4032","DOI":"10.1200\/JCO.2025.43.16_suppl.4032","article-title":"First-Line Osemitamab (TST001) plus Nivolumab and CAPOX for Advanced G\/GEJ Cancer (TranStar102): Updated Results of Cohort G from a Phase I\/IIa Study","volume":"43","author":"Gong","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"4044","DOI":"10.1200\/JCO.2025.43.16_suppl.4044","article-title":"Second-Line ASKB589 plus Chemotherapy for Advanced Gastric or Gastroesophageal Cancers: Results from Cohort 5 of a Phase I\/II Study","volume":"43","author":"Zhang","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1200\/JCO.2025.43.4_suppl.454","article-title":"Updated Efficacy Results of ASKB589 Combined with CAPOX and PD-1 Inhibitor as First-Line Treatment for Metastatic Gastric\/Gastro-Esophageal Junction (G\/GEJ) Adenocarcinoma from a Phase Ib\/II Study","volume":"43","author":"Peng","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1200\/JCO.2025.43.4_suppl.431","article-title":"FG-M108 plus Capecitabine and Oxaliplatin (CAPOX) for First-Line Treatment of CLDN18.2+\/HER2- Advanced Gastric\/Gastroesophageal Junction Adenocarcinoma (GC): Update Results of a Phase I\/II Trial to Determine RP2D","volume":"43","author":"Gong","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"4188","DOI":"10.1200\/JCO.2025.43.16_suppl.4188","article-title":"Preliminary Result of a Phase Ib Study: Efficacy and Safety of FG-M108 plus Gemcitabine and Nab-Paclitaxel in Patients with Claudin18.2-Positive, Locally Advanced, Unresectable, or Metastatic Pancreatic Cancer","volume":"43","author":"Liu","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_58","doi-asserted-by":"crossref","unstructured":"Inamoto, R., Takahashi, N., and Yamada, Y. (2023). Claudin18.2 in Advanced Gastric Cancer. Cancers, 15.","DOI":"10.3390\/cancers15245742"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"5183","DOI":"10.1158\/1538-7445.AM2020-5183","article-title":"Abstract 5183: The Preclinical Characterization of TST001, a Novel Humanized Anti-Claudin18.2 mAb with Enhanced Binding Affinity and Anti-Tumor Activity","volume":"80","author":"Teng","year":"2020","journal-title":"Cancer Res."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"TPS4176","DOI":"10.1200\/JCO.2023.41.16_suppl.TPS4176","article-title":"A Multi-Cohort Phase I\/IIa Clinical Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of TST001 Administered as a Monotherapy, with Nivolumab or Standard of Care in Patients with Locally Advanced or Metastatic Solid Tumors: TransStar101","volume":"41","author":"Janjigian","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"CT132","DOI":"10.1158\/1538-7445.AM2024-CT132","article-title":"Abstract CT132: A Phase I\/IIa Clinical Trial (TranStar101) to Evaluate the Safety, Tolerability and Pharmacokinetics of OSEMITAMAB Administered as Monotherapy or in Combination with Nivolumab or Standard of Care in Patients with Locally Advanced or Metastatic Solid Tumors","volume":"84","author":"Janjigian","year":"2024","journal-title":"Cancer Res."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"S858","DOI":"10.1016\/j.annonc.2023.09.1437","article-title":"1524P First-Line TST001 plus Capecitabine and Oxaliplatin (CAPOX) for Advanced G\/GEJ Cancer with CLDN18.2 Positive Overall Survival Data from Study Transtar102-Cohort C","volume":"34","author":"Shen","year":"2023","journal-title":"Ann. Oncol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1200\/JCO.2023.41.4_suppl.397","article-title":"A Phase I\/II Study of ASKB589 (Anti-Claudin 18.2 [CLDN18.2] Monoclonal Antibody) in Patients with Solid Tumors","volume":"41","author":"Zhang","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/S1470-2045(24)00636-3","article-title":"Claudin 18.2-Targeting Antibody\u2013Drug Conjugate CMG901 in Patients with Advanced Gastric or Gastro-Oesophageal Junction Cancer (KYM901): A Multicentre, Open-Label, Single-Arm, Phase 1 Trial","volume":"26","author":"Ruan","year":"2025","journal-title":"Lancet Oncol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"TPS3163","DOI":"10.1200\/JCO.2024.42.16_suppl.TPS3163","article-title":"CLARITY-PanTumor01: A Phase 2 Trial of the Claudin 18.2-Specific Antibody-Drug Conjugate AZD0901 (CMG901) in Patients with CLDN18.2-Expressing Advanced Solid Tumors","volume":"42","author":"Raufi","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"TPS507","DOI":"10.1200\/JCO.2025.43.4_suppl.TPS507","article-title":"CLARITY-Gastric 01: A Randomized Phase 3 Study of AZD0901, a Claudin18.2 (CLDN18.2)-Targeted Antibody-Drug Conjugate, in Second- or Later-Line (2L+) Advanced Gastric or Gastroesophageal Junction Cancer (GC\/GEJC)","volume":"43","author":"Janjigian","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"TPS4182","DOI":"10.1200\/JCO.2024.42.16_suppl.TPS4182","article-title":"GEMINI-Gastric: A Phase 2 Study of Novel Treatment Combinations in Patients with Locally Advanced Unresectable or Metastatic Gastric Cancers","volume":"42","author":"Shen","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"3028","DOI":"10.1200\/JCO.2024.42.16_suppl.3028","article-title":"A Phase 1\/2 Study of LM-302, an Anti-Claudin 18.2 (CLDN18.2) Antibody-Drug Conjugate in Patients with Advanced Gastric\/Gastroesophageal Junction Cancer","volume":"42","author":"Bai","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"4039","DOI":"10.1200\/JCO.2025.43.16_suppl.4039","article-title":"Efficacy and Safety of LM-302 (Anti-Claudin 18.2 ADC) in Combination with Anti-PD-1 Therapy for Advanced Gastric, Gastroesophageal Junction Cancer and Esophageal Adenocarcinoma: Early-Phase Study Results","volume":"43","author":"Jiang","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"e16152","DOI":"10.1200\/JCO.2024.42.16_suppl.e16152","article-title":"Two Stage, Multi-Center Trial of Cadonilimab and LM-302 for Patients with CLDN18.2+ Biliary Tract Cancer (BTC) That Failed Chemotherapy and PD-(L)1 Antibody (ZSAB-Calm)","volume":"42","author":"Fan","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"3037","DOI":"10.1038\/s41591-025-03781-w","article-title":"The Antibody\u2013Drug Conjugate SHR-A1904 for Targeting CLDN18.2 in Advanced Gastric or Gastroesophageal Junction Cancer: A Phase 1 Trial","volume":"31","author":"Ruan","year":"2025","journal-title":"Nat. Med."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"3028","DOI":"10.1038\/s41591-025-03783-8","article-title":"CLDN18.2\u2013Targeting Antibody\u2013Drug Conjugate IBI343 in Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: A Phase 1 Trial","volume":"31","author":"Liu","year":"2025","journal-title":"Nat. Med."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"S903","DOI":"10.1016\/j.annonc.2024.08.1522","article-title":"1456P First in Human Phase I\/II Trial of Claudin 18.2 ADC RC118 in Patients with Advanced Gastric\/Gastroesophageal Junction Cancer","volume":"35","author":"Liu","year":"2024","journal-title":"Ann. Oncol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"3026","DOI":"10.1200\/JCO.2025.43.16_suppl.3026","article-title":"First in Human Phase I Study of TQB2103, a Claudin18.2 (CLDN18.2) Targeted Antibody-Drug Conjugate (ADC), in Patients with Advanced Solid Tumors","volume":"43","author":"Cheng","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"S151","DOI":"10.1016\/j.annonc.2025.05.404","article-title":"388MO Preliminary Safety and Efficacy of Givastomig, a Novel Claudin 18.2\/4-1BB Bispecific Antibody, in Combination with Nivolumab and mFOLFOX in Metastatic Gastroesophageal Carcinoma (mGEC)","volume":"36","author":"Klempner","year":"2025","journal-title":"Ann. Oncol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"S1202","DOI":"10.1016\/j.annonc.2025.08.2756","article-title":"2137P ASP2138 Monotherapy in Patients (Pts) with Claudin 18 Isoform 2 (CLDN18.2)+, Advanced Solid Tumors: Phase I\/Ib Trial","volume":"36","author":"Shitara","year":"2025","journal-title":"Ann. Oncol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"2527","DOI":"10.1200\/JCO.2025.43.16_suppl.2527","article-title":"Safety and Efficacy of QLS31905 in Patients with Advanced Solid Tumors: Updated Data from Phase 1 Study","volume":"43","author":"Wang","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"2662","DOI":"10.1200\/JCO.2024.42.16_suppl.2662","article-title":"First-in-Human Phase I\/II Safety and Preliminary Efficacy of PM1032, a Bispecific Antibody Targeting CLDN18.2 and 4-1BB, in Patients with Advanced Solid Tumors","volume":"42","author":"Guo","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1200\/JCO.2024.42.16_suppl.2519","article-title":"Safety and Preliminary Efficacy Results of IBI389, an Anti-CLDN18.2\/CD3 Bispecific Antibody, in Patients with Solid Tumors and Gastric or Gastro-Esophageal Tumors: A Phase 1 Dose Escalation and Expansion Study","volume":"42","author":"Zheng","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1038\/nri2526","article-title":"The Role of TNF Superfamily Members in T-Cell Function and Diseases","volume":"9","author":"Croft","year":"2009","journal-title":"Nat. Rev. Immunol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"e006704","DOI":"10.1136\/jitc-2023-006704","article-title":"CLDN18.2 and 4-1BB Bispecific Antibody Givastomig Exerts Antitumor Activity through CLDN18.2-Expressing Tumor-Directed T-Cell Activation","volume":"11","author":"Gao","year":"2023","journal-title":"J. Immunother. Cancer"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"2962","DOI":"10.1158\/1538-7445.AM2023-2962","article-title":"Abstract 2962: ASP2138, a Novel 2+1 Format, Claudin 18.2 x CD3 Bispecific Antibody, Demonstrates Selectivity and Activity in Preclinical Cancer Models","volume":"83","author":"Nakazawa","year":"2023","journal-title":"Cancer Res."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1038\/s41392-025-02269-w","article-title":"CAR-T Cell Therapy for Cancer: Current Challenges and Future Directions","volume":"10","author":"Zugasti","year":"2025","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1200\/JCO.2019.37.15_suppl.2509","article-title":"Phase I Trial of Claudin 18.2-Specific Chimeric Antigen Receptor T Cells for Advanced Gastric and Pancreatic Adenocarcinoma","volume":"37","author":"Zhan","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1038\/s41591-024-03037-z","article-title":"Claudin18.2-Specific CAR T Cells in Gastrointestinal Cancers: Phase 1 Trial Final Results","volume":"30","author":"Qi","year":"2024","journal-title":"Nat. Med."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1200\/JCO.2024.42.3_suppl.356","article-title":"CLDN18.2 Chimeric Antigen Receptor T Cell Therapy for Patients with Advanced Gastric and Pancreatic Adenocarcinoma: Results of ELIMYN18.2 Phase 1b Clinical Trial","volume":"42","author":"Botta","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"2565","DOI":"10.1200\/JCO.23.02314","article-title":"Safety and Efficacy of CT041 in Patients With Refractory Metastatic Pancreatic Cancer: A Pooled Analysis of Two Early-Phase Trials","volume":"42","author":"Qi","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1200\/JCO.2025.43.4_suppl.828","article-title":"A Phase 1\/2 Study Evaluating the Safety and Efficacy of Autologous TAC T Cells in Subjects with Claudin 18.2+ Advanced Solid Tumors","volume":"43","author":"Dumbrava","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"2501","DOI":"10.1200\/JCO.2024.42.16_suppl.2501","article-title":"Claudin18.2-Targeted Chimeric Antigen Receptor T Cell-Therapy for Patients with Gastrointestinal Cancers: Final Results of CT041-CG4006 Phase 1 Trial","volume":"42","author":"Qi","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"4003","DOI":"10.1200\/JCO.2025.43.16_suppl.4003","article-title":"Claudin18.2-Specific CAR T Cells (Satri-Cel) versus Treatment of Physician\u2019s Choice (TPC) for Previously Treated Advanced Gastric or Gastroesophageal Junction Cancer (G\/GEJC): Primary Results from a Randomized, Open-Label, Phase II Trial (CT041-ST-01)","volume":"43","author":"Qi","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1016\/S0140-6736(25)00860-8","article-title":"Claudin-18 Isoform 2-Specific CAR T-Cell Therapy (Satri-Cel) versus Treatment of Physician\u2019s Choice for Previously Treated Advanced Gastric or Gastro-Oesophageal Junction Cancer (CT041-ST-01): A Randomised, Open-Label, Phase 2 Trial","volume":"405","author":"Qi","year":"2025","journal-title":"Lancet"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1158\/2326-6066.CIR-24-0138","article-title":"Preclinical Development of T Cells Engineered to Express a T-Cell Antigen Coupler Targeting Claudin 18.2\u2013Positive Solid Tumors","volume":"13","author":"Xu","year":"2025","journal-title":"Cancer Immunol. Res."},{"key":"ref_93","doi-asserted-by":"crossref","unstructured":"Jia, K., Chen, Y., Sun, Y., Hu, Y., Jiao, L., Ma, J., Yuan, J., Qi, C., Li, Y., and Gong, J. (2022). Multiplex Immunohistochemistry Defines the Tumor Immune Microenvironment and Immunotherapeutic Outcome in CLDN18.2-Positive Gastric Cancer. BMC Med., 20.","DOI":"10.1186\/s12916-022-02421-1"},{"key":"ref_94","doi-asserted-by":"crossref","unstructured":"Korpan, M., Puhr, H.C., Berger, J.M., Friedrich, A., Prager, G.W., Preusser, M., and Ilhan-Mutlu, A. (2025). Current Landscape of Molecular Biomarkers in Gastroesophageal Tumors and Potential Strategies for Co-Expression Patterns. Cancers, 17.","DOI":"10.3390\/cancers17030340"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"103012","DOI":"10.1016\/j.ctrv.2025.103012","article-title":"Combining Antibody-Drug Conjugates with Immune Checkpoint Inhibitors: A New Paradigm for Breast Cancer Therapy","volume":"140","author":"Xu","year":"2025","journal-title":"Cancer Treat. Rev."},{"key":"ref_96","first-page":"61","article-title":"Claudin 18.2 Immunohistochemistry Expression in Gastric Cancer: A Systematic Review","volume":"33","author":"Patriarca","year":"2025","journal-title":"Appl. Immunohistochem. Mol. Morphol. AIMM"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"viii32","DOI":"10.1093\/annonc\/mdy269.101","article-title":"Prevalence of CLDN18.2, HER2 and PD-L1 in Gastric Cancer Samples","volume":"29","author":"Moran","year":"2018","journal-title":"Ann. Oncol."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1007\/s10120-024-01505-6","article-title":"Claudin-18 Status and Its Correlation with HER2 and PD-L1 Expression in Gastric Cancer with Peritoneal Dissemination","volume":"27","author":"Ogawa","year":"2024","journal-title":"Gastric Cancer"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1007\/s10637-024-01417-3","article-title":"A Bispecific Antibody Targeting HER2 and CLDN18.2 Eliminates Gastric Cancer Cells Expressing Dual Antigens by Enhancing the Immune Effector Function","volume":"42","author":"Yue","year":"2024","journal-title":"Investig. New Drugs"},{"key":"ref_100","doi-asserted-by":"crossref","unstructured":"Shao, Q., Deng, J., Wu, H., and Huang, Z. (2025). HER2-Positive Gastric Cancer: From Targeted Therapy to CAR-T Cell Therapy. Front. Immunol., 16.","DOI":"10.3389\/fimmu.2025.1560280"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"e012683","DOI":"10.1136\/jitc-2025-012683","article-title":"Dynamic Modulation of Claudin18.2 Expression and Remodeling of the Tumor Microenvironment in Gastric Cancer during Chemo-Immunotherapy","volume":"13","author":"Lim","year":"2025","journal-title":"J. Immunother. Cancer"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.cll.2021.04.005","article-title":"Antigen Loss after Targeted Immunotherapy in Hematological Malignancies","volume":"41","author":"Zhou","year":"2021","journal-title":"Clin. Lab. Med."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1002\/jcb.23095","article-title":"Transcriptional Regulation of Claudin-18 via Specific Protein Kinase C Signaling Pathways and Modification of DNA Methylation in Human Pancreatic Cancer Cells","volume":"112","author":"Ito","year":"2011","journal-title":"J. Cell Biochem."},{"key":"ref_104","doi-asserted-by":"crossref","unstructured":"Ma, M., Sun, J., Liu, Z., Ouyang, S., Zhang, Z., Zeng, Z., Li, J., and Kang, W. (2022). The Immune Microenvironment in Gastric Cancer: Prognostic Prediction. Front. Oncol., 12.","DOI":"10.3389\/fonc.2022.836389"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"R921","DOI":"10.1016\/j.cub.2020.06.081","article-title":"Tumor Microenvironment","volume":"30","author":"Anderson","year":"2020","journal-title":"Curr. Biol."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"e471716","DOI":"10.1200\/EDBK-25-471716","article-title":"Cell-Based Therapies in GI Cancers: Current Landscape and Future Directions","volume":"45","author":"Nakayama","year":"2024","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1038\/s41416-025-02981-y","article-title":"Claudin18.2-Positive Gastric Cancer-Specific Changes in Neoadjuvant Chemotherapy-Driven Immunosuppressive Tumor Microenvironment: Cellular and Molecular Biology","volume":"132","author":"Tsutsumi","year":"2025","journal-title":"Br. J. Cancer"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/s41575-023-00840-w","article-title":"Therapeutic Developments in Pancreatic Cancer","volume":"21","author":"Hu","year":"2024","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_109","doi-asserted-by":"crossref","unstructured":"Principe, D.R., Timbers, K.E., Atia, L.G., Koch, R.M., and Rana, A. (2021). TGF\u03b2 Signaling in the Pancreatic Tumor Microenvironment. Cancers, 13.","DOI":"10.3390\/cancers13205086"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1038\/s41575-022-00591-0","article-title":"The Immune Microenvironment in Gastric Adenocarcinoma","volume":"19","author":"Zavros","year":"2022","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1186\/s13287-020-02128-1","article-title":"CAR T Cells in Solid Tumors: Challenges and Opportunities","volume":"12","author":"Marofi","year":"2021","journal-title":"Stem Cell Res. Ther."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"5413","DOI":"10.1158\/1078-0432.CCR-24-1853","article-title":"Preclinical Evaluation of AZD6422, an Armored Chimeric Antigen Receptor T Cell Targeting CLDN18.2 in Gastric, Pancreatic, and Esophageal Cancer","volume":"30","author":"Barrett","year":"2024","journal-title":"Clin. Cancer Res."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1186\/s12967-023-04080-z","article-title":"FAP-Targeted CAR-T Suppresses MDSCs Recruitment to Improve the Antitumor Efficacy of Claudin18.2-Targeted CAR-T against Pancreatic Cancer","volume":"21","author":"Liu","year":"2023","journal-title":"J. Transl. Med."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.ccell.2019.09.006","article-title":"Combination Immunotherapy with CAR T Cells and Checkpoint Blockade for the Treatment of Solid Tumors","volume":"36","author":"Grosser","year":"2019","journal-title":"Cancer Cell"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"2535","DOI":"10.1021\/acs.molpharmaceut.4c01427","article-title":"Targeted Radionuclide Therapy of CLDN18.2-Positive Gastric Cancer with [131I]I-Zolbetuximab: An In Vitro and In Vivo Study","volume":"22","author":"Wang","year":"2025","journal-title":"Mol. Pharm."},{"key":"ref_116","doi-asserted-by":"crossref","unstructured":"Bordeau, B.M., and Balthasar, J.P. (2021). Strategies to Enhance Monoclonal Antibody Uptake and Distribution in Solid Tumors. Cancer Biol. Med., 18.","DOI":"10.20892\/j.issn.2095-3941.2020.0704"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1038\/s41575-025-01062-y","article-title":"CAR T Cell Therapies in Gastrointestinal Cancers: Current Clinical Trials and Strategies to Overcome Challenges","volume":"22","author":"Abken","year":"2025","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"2500546","DOI":"10.1002\/adhm.202500546","article-title":"CLDN18.2 CAR-Derived Extracellular Vesicle Immunotherapy Improves Outcome in Murine Pancreatic Cancer","volume":"14","author":"Qing","year":"2025","journal-title":"Adv. Healthc. Mater."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/17\/23\/3764\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T15:42:45Z","timestamp":1764085365000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/17\/23\/3764"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,25]]},"references-count":118,"journal-issue":{"issue":"23","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["cancers17233764"],"URL":"https:\/\/doi.org\/10.3390\/cancers17233764","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,25]]}}}